Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation

Ramzi Abboud, Mark A. Schroeder, Michael P Rettig, Reyka G Jayasinghe, Feng Gao, Jeremy Eisele, Leah Gehrs, Julie K. Ritchey, Jaebok Choi, Camille N Abboud, Iskra Pusic, Meagan A Jacoby, Peter Westervelt, Matthew Christopher, Amanda F. Cashen, Armin Ghobadi, Keith Stockerl-Goldstein, Geoffrey L Uy, John F. DiPersio

Blood blood.2024026497.

https://doi.org/10.1182/blood.2024026497

Published: 2024

Includes: Supplemental data

Journal Articles

Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

Blood (2024) 144 (Supplement 1): 773.

https://doi.org/10.1182/blood-2024-201057

Published: 2024

Journal Articles

Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

Blood (2024) 144 (Supplement 1): 224.

https://doi.org/10.1182/blood-2024-201694

Published: 2024

Journal Articles

Convenience Versus Continuity: A Natural History Study of a Newly Opened Plasma Cell Disorders Clinic in an Underserved Community and Desire for Transfer of Care Among Previously Diagnosed Patients

Michael Slade, Ravi Vij, Keith Stockerl-Goldstein, Mark A. Schroeder, Angela Vickroy, Margaret Kavanaugh, Carmen Wilson, Mark Fiala

Blood (2024) 144 (Supplement 1): 3653.

https://doi.org/10.1182/blood-2024-203469

Published: 2024

Journal Articles

Real-World Experience with Elotuzumab, Pomalidomide, and Dexamethasone As Second or Third-Line Therapy in Relapsed and Refractory Multiple Myeloma

Akhil Kesaraju, Alexa Loncharich, Keith Stockerl-Goldstein, Mark A. Schroeder, Angela Vickroy, Ravi Vij, Michael Slade

Blood (2024) 144 (Supplement 1): 6936.

https://doi.org/10.1182/blood-2024-208241

Published: 2024

Journal Articles

Impact of Absolute Lymphocyte Counts (ALC) on Outcomes Following Bispecific Antibody Therapy in Patients with Relapsed/Refractory Multiple Myeloma Patients: A Single Center Real-World Experience

Yash Shah, Mark Fiala, Keith Stockerl-Goldstein, Mark A. Schroeder, Ravi Vij, Zachary D. Crees, Michael Slade

Blood (2024) 144 (Supplement 1): 3792.1.

https://doi.org/10.1182/blood-2024-209293

Published: 2024

Journal Articles

Evaluating Diagnostic Performance of Light Chain Dimerization By Mass Spectrometry to Distinguish between AL Amyloidosis and Monoclonal Gammopathy of Undetermined Significance

Alexa Loncharich, Mark Fiala, Julie Fortier, Keith Stockerl-Goldstein, Ravi Vij, Mark A. Schroeder, Mark Zaydman, Michael Slade, Mariya Liyasova

Blood (2024) 144 (Supplement 1): 1921.

https://doi.org/10.1182/blood-2024-211395

Published: 2024

Journal Articles

Prolonged CXCR4 Receptor Occupancy By Motixafortide Following a Single Subcutaneous Injection Is Associated with Extended Mobilization of CD34+ Cells in Peripheral Blood for > 24 Hours

Zachary David Crees, Keith Stockerl-Goldstein, Ella Sorani, Debby Ickowicz, Liron Darvish, John F. DiPersio

Blood (2023) 142 (Supplement 1): 5777.

https://doi.org/10.1182/blood-2023-184608

Published: 2023

Journal Articles

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome with T-Cell Replete Peripheral Blood Haploidentical Transplantation

Ramzi Abboud, Mark A. Schroeder, Michael P. Rettig, Feng Gao, Julie K. Ritchey, Camille N. Abboud, Iskra Pusic, Peter Westervelt, Amanda F Cashen, Matt Christopher, Armin Ghobadi, Ramzi Abboud, Keith Stockerl-Goldstein, Geoffrey L Uy, John F. DiPersio, Leah Gehrs

Blood (2023) 142 (Supplement 1): 651.

https://doi.org/10.1182/blood-2023-180289

Published: 2023

Journal Articles

Use of Combination Premedication Prior to Motixafortide Administration Reduced Severity and Frequency of AEs in the Phase 3 Genesis Trial - a Single Center Analysis

Zachary David Crees, Keith Stockerl-Goldstein, Mark A. Schroeder, Ravi Vij, Ella Sorani, Irit Gliko Kabir, Inbal Goldstein, Tzipi Lustig, Shaul Kadosh, John F. DiPersio

Blood (2023) 142 (Supplement 1): 3522.

https://doi.org/10.1182/blood-2023-181452

Published: 2023

Journal Articles

Measurable Residual Disease Status By Clonotypic Mass Spectrometry with Easym Assay Predicts Outcomes Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Michael Slade, Abir Khaled, Mark Fiala, Zac McDonald, Mariya Liyasova, Julie Fortier, Mark Zaydman, Sarah Kelley, Zachary David Crees, Mark A. Schroeder, Keith Stockerl-Goldstein, Liqiang Yang, Ravi Vij

Blood (2023) 142 (Supplement 1): 3354.

https://doi.org/10.1182/blood-2023-172440

Published: 2023

Journal Articles

Patient Recorded Outcomes from a Randomized, Controlled Phase 2 Trial of E-Selectin Inhibition with Uproleselan Vs Placebo to Reduce GI Toxicity during Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Meaghan Ryan, Zachary David Crees, Michael Slade, Mark A. Schroeder, Ravi Vij, Geoffrey L Uy, Keith Stockerl-Goldstein

Blood (2023) 142 (Supplement 1): 2217.

https://doi.org/10.1182/blood-2023-179604

Published: 2023

Journal Articles

DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-139332

Published: 2020

Journal Articles

Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft

Blood (2017) 129 (19): 2680–2692.

https://doi.org/10.1182/blood-2016-09-739722

Published: 2017

Includes: Supplemental data

Journal Articles

A Phase II Study of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Mark A Fiala, BS, CCRP, Jesse Keller, MD, Jeevan Sekhar, MD, Connie Ceriotti, RN, BSN, Camille N. Abboud, MD, John F DiPersio, MD PhD, Michael H. Tomasson, MD, Tanya M Wildes, MD MSCI, Keith Stockerl-Goldstein, Ravi Vij, MD MBA

Blood (2016) 128 (22): 3329.

https://doi.org/10.1182/blood.V128.22.3329.3329

Published: 2016

Journal Articles

A Phase I Study of the Safety and Feasibility of Bortezomib in Combination with G-CSF for Stem Cell Mobilization in Patients with Multiple Myeloma

Armin Ghobadi, MD, Mark A Fiala, BS, CCRP, Geoffrey L. Uy, MD, Keith Stockerl-Goldstein, Ravi Vij, MD MBA, John F DiPersio, MD PhD

Blood (2016) 128 (22): 3381.

https://doi.org/10.1182/blood.V128.22.3381.3381

Published: 2016

Journal Articles

The Efficacy of Salvage Autologous Stem Cell Transplant for Patients with Multiple Myeloma Who Received Maintenance Therapy Following Initial Transplant

Justin A King, Mark A Fiala, BS, CCRP, Daniel R Kohnen, Tanya M Wildes, MD, Keith Stockerl-Goldstein, Ravi Vij, MD MBA

Blood (2016) 128 (22): 3563.

https://doi.org/10.1182/blood.V128.22.3563.3563

Published: 2016

Journal Articles

Next Generation Sequencing Based Revised International Staging System (R-ISS) for Multiple Myeloma

Mark A Fiala, BS, CCRP, James Dukeman, BS, Keith Stockerl-Goldstein, Michael H. Tomasson, MD, Tanya M Wildes, MD MSCI, Daniel Auclair, PhD, Ravi Vij, MD MBA

Blood (2016) 128 (22): 2349.

https://doi.org/10.1182/blood.V128.22.2349.2349

Published: 2016

Journal Articles

The Real-World Characteristics and Outcomes of Newly Diagnosed Myeloma Patients Ineligible for Clinical Trials

Mark A Fiala, BS, CCRP, James Dukeman, BS, Keith Stockerl-Goldstein, Michael H. Tomasson, MD, Tanya M Wildes, MD MSCI, Ravi Vij, MD MBA

Blood (2016) 128 (22): 2350.

https://doi.org/10.1182/blood.V128.22.2350.2350

Published: 2016

Journal Articles

Imaging of Plasma Cell Dyscrasias with FDG-PET/MRI: A Single-Center Experience

Tyler J Fraum, MD, Ephraim Parent, MD PhD, Monica Shokeen, PhD, Keith Stockerl-Goldstein, Michelle Miller-Thomas, MD, Farrokh Dehdashti, MD, Ravi Vij, MD, Kathryn J Fowler, MD

Blood (2016) 128 (22): 5611.

https://doi.org/10.1182/blood.V128.22.5611.5611

Published: 2016

NARROW

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation

Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

Convenience Versus Continuity: A Natural History Study of a Newly Opened Plasma Cell Disorders Clinic in an Underserved Community and Desire for Transfer of Care Among Previously Diagnosed Patients

Real-World Experience with Elotuzumab, Pomalidomide, and Dexamethasone As Second or Third-Line Therapy in Relapsed and Refractory Multiple Myeloma

Impact of Absolute Lymphocyte Counts (ALC) on Outcomes Following Bispecific Antibody Therapy in Patients with Relapsed/Refractory Multiple Myeloma Patients: A Single Center Real-World Experience

Evaluating Diagnostic Performance of Light Chain Dimerization By Mass Spectrometry to Distinguish between AL Amyloidosis and Monoclonal Gammopathy of Undetermined Significance

Prolonged CXCR4 Receptor Occupancy By Motixafortide Following a Single Subcutaneous Injection Is Associated with Extended Mobilization of CD34+ Cells in Peripheral Blood for > 24 Hours

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome with T-Cell Replete Peripheral Blood Haploidentical Transplantation

Use of Combination Premedication Prior to Motixafortide Administration Reduced Severity and Frequency of AEs in the Phase 3 Genesis Trial - a Single Center Analysis

Measurable Residual Disease Status By Clonotypic Mass Spectrometry with Easym Assay Predicts Outcomes Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Patient Recorded Outcomes from a Randomized, Controlled Phase 2 Trial of E-Selectin Inhibition with Uproleselan Vs Placebo to Reduce GI Toxicity during Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft

A Phase II Study of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for Relapsed or Refractory Multiple Myeloma

A Phase I Study of the Safety and Feasibility of Bortezomib in Combination with G-CSF for Stem Cell Mobilization in Patients with Multiple Myeloma

The Efficacy of Salvage Autologous Stem Cell Transplant for Patients with Multiple Myeloma Who Received Maintenance Therapy Following Initial Transplant

Next Generation Sequencing Based Revised International Staging System (R-ISS) for Multiple Myeloma

The Real-World Characteristics and Outcomes of Newly Diagnosed Myeloma Patients Ineligible for Clinical Trials

Imaging of Plasma Cell Dyscrasias with FDG-PET/MRI: A Single-Center Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only